DNAJA1 has been identified as a potential therapeutic target for treating pancreatic ductal adenocarcinoma (PDAC) [4,5,6,7], which accounts for more than 90% of all pancreatic cancers [8]. The gene discussed is DNAJA1; the disease is familial pancreatic carcinoma.